GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax Labs (Nasdaq: GOVX) announced it will report its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. markets close. The biotechnology company, which develops immunotherapies and vaccines against cancers and infectious diseases, will host a conference call and webcast with Q&A at 4:30 PM ET. Management will provide a corporate update and discuss financial results. Participants can access the call through registration, and an audio webcast archive will be available on the company's website for at least 90 days following the event.
GeoVax Labs (Nasdaq: GOVX) ha annunciato che renderà noti i suoi risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024, dopo la chiusura dei mercati statunitensi. L'azienda biotecnologica, che sviluppa immunoterapie e vaccini contro il cancro e le malattie infettive, ospiterà una teleconferenza e una trasmissione web con sessione di domande e risposte alle 16:30 ET. La direzione fornirà un aggiornamento aziendale e discuterà i risultati finanziari. I partecipanti possono accedere alla chiamata previa registrazione, e un'archivio audio della trasmissione sarà disponibile sul sito web dell'azienda per almeno 90 giorni dopo l'evento.
GeoVax Labs (Nasdaq: GOVX) anunció que reportará sus resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024, después del cierre de los mercados de EE. UU. La compañía biotecnológica, que desarrolla inmunoterapias y vacunas contra el cáncer y enfermedades infecciosas, llevará a cabo una llamada de conferencia y una transmisión web con preguntas y respuestas a las 4:30 PM ET. La dirección proporcionará una actualización corporativa y discutirá los resultados financieros. Los participantes pueden acceder a la llamada a través de registro, y un archivo de transmisión de audio estará disponible en el sitio web de la compañía durante al menos 90 días después del evento.
GeoVax Labs (Nasdaq: GOVX)는 2024년 11월 12일 화요일, 미국 시장 마감 이후에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 암 및 감염병에 대한 면역 요법 및 백신을 개발하는 생명공학 회사는 오후 4:30 ET에 질문 및 답변이 포함된 컨퍼런스 콜과 웹케스트를 진행합니다. 경영진은 기업 업데이트를 제공하고 재무 결과를 논의할 것입니다. 참가자는 등록을 통해 통화에 접근할 수 있으며, 이벤트 이후 최소 90일 동안 회사 웹사이트에서 오디오 웹캐스트 아카이브를 이용할 수 있습니다.
GeoVax Labs (Nasdaq: GOVX) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024, après la fermeture des marchés américains. La société de biotechnologie, qui développe des immunothérapies et des vaccins contre le cancer et les maladies infectieuses, organisera une conférence téléphonique et un webinaire avec une session de questions-réponses à 16h30 HE. La direction fournira une mise à jour de l'entreprise et discutera des résultats financiers. Les participants peuvent accéder à l'appel via une inscription, et une archive audio du webinaire sera disponible sur le site Web de l'entreprise pendant au moins 90 jours après l'événement.
GeoVax Labs (Nasdaq: GOVX) gab bekannt, dass es am Dienstag, den 12. November 2024, nach dem Handelsschluss der US-Märkte seine finanziellen Ergebnisse für das 3. Quartal 2024 bekannt geben wird. Das Biotechnologieunternehmen, das Immuntherapien und Impfstoffe gegen Krebs und Infektionskrankheiten entwickelt, wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast mit Fragen und Antworten veranstalten. Das Management wird ein Unternehmensupdate geben und die finanziellen Ergebnisse erörtern. Teilnehmer können sich über eine Registrierung in den Anruf einwählen, und ein Audio-Webcast-Archiv wird für mindestens 90 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
GeoVax to Host Conference Call at 4:30 PM ET
ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results.
Conference Call Details
To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the GeoVax website at geovax.com/investors. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archive of the audio webcast will be available on GeoVax’s website approximately two hours after the conference call and will remain available for at least 90 days following the event.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 |
FAQ
When will GeoVax (GOVX) report Q3 2024 earnings?
What time is GeoVax's (GOVX) Q3 2024 earnings call?
How can investors access GeoVax's (GOVX) Q3 2024 earnings call?
